Evidence map›Paper›PMID 38877763›Full record

ArticleThe Journal of infectious diseases2024

Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022.

Eric P F Chow, Kerrie Stevens, Vesna De Petra, Marcus Y Chen, Catriona S Bradshaw, Norelle L Sherry, Lindley A Barbee, Lenka A Vodstrcil, Ivette Aguirre, Kate L Seib and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eric P F ChowMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID 0000-0003-1766-0657
Kerrie StevensMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Vesna De PetraMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.
Marcus Y ChenMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID 0000-0002-8924-2043
Catriona S BradshawMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID 0000-0002-6643-5678
Norelle L SherryMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-7789-8360
Lindley A BarbeeDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Lenka A VodstrcilMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID 0000-0003-3679-9195
Ivette AguirreMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.
Kate L SeibInstitute for Glycomics, Griffith University, Southport, Queensland, Australia.ORCID 0000-0002-7094-3528
Kate MaddafordMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID 0000-0001-5213-1289
Deborah A WilliamsonVictorian Infectious Disease Reference Laboratory, The Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-7363-6665
Benjamin P HowdenMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-0237-1473
Christopher K FairleyMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID 0000-0001-9081-1664

Funding

Australian National Health and Medical Research CouncilAustralian National Health and Medical Research Council Leadership Investigator Grant GNT1172900Emerging Leadership Investigator Grant GNT1172873
6 · The paper itself

Abstract

While ceftriaxone remains the first-line treatment for gonorrhea, the US Centers for Disease Control and Prevention recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021 and 2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176), and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was highest among women (16.4%, 10/61), followed by men who have sex with women (6.4%, 7/109) and men who have sex with men (5.8%, 57/982). The prevalence of cefixime-resistant N gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; thus, cefixime treatment would have limited benefits in Australia.

Indexed as

Anti-Bacterial AgentsCefiximeGonorrheaNeisseria gonorrhoeaeAdolescentAdultAustraliaAzithromycinCeftriaxoneDrug Resistance, BacterialFemaleHumansMaleMicrobial Sensitivity TestsPrevalenceYoung AdultAnti-Bacterial AgentsAzithromycinCefiximeCeftriaxoneantimicrobial resistancegonorrheaNeisseria gonorrhoeaeresistancetreatment

Identifiers

PMID38877763
PMCPMC11565866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.